)
Visual
test
SoftOx Solutions
SoftOx Solutions (SOFTX) investor relations material
SoftOx Solutions Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary26 Nov, 2025
Executive summary
Completed financial restructuring, with new board and leadership focusing on inhalation therapeutics for chronic lung diseases and medical countermeasures.
Operations strategically narrowed to focus on inhaled antimicrobial pharmaceuticals targeting significant unmet needs in respiratory infections.
Clinical focus shifted to chronic lung diseases, especially cystic fibrosis and non-CF bronchiectasis, with proof-of-concept trial planned.
Defense subsidiary continues work on inhaled countermeasures against biological threats, funded by European Defence Fund and Norwegian Ministry of Defence.
Financial highlights
Q3 2025 pre-tax loss of NOK 5.5 million, improved from NOK 17.9 million loss in Q3 2024.
First three quarters 2025 pre-tax loss of NOK 6.9 million, significantly reduced from NOK 46.9 million loss in the same period 2024.
Total operating revenue for first three quarters 2025 was NOK 12 million, up from NOK 6.3 million in 2024, mainly from grants.
Operating expenses for first three quarters 2025 were NOK 19.5 million, down from NOK 37.9 million in 2024.
Cash and cash equivalents at end of Q3 2025 were NOK 20.1 million, up from NOK 14.5 million at Q3 2024.
Outlook and guidance
Proof-of-concept clinical trial for inhaled solution to start Q1 2026, with completion expected Q1 2027.
First healthy volunteer enrollment in Q1 2026; trial timelines and budgets remain unchanged.
Ongoing efforts to secure approximately EUR 8 million in additional funding for key clinical activities.
Medical countermeasure Phase 1 trial to be initiated in Q1 2026.
PoC shift: What specific patient factors drove it?
How will the EUR 8M funding gap be secured?
Defense program: How does it leverage SIS tech?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- BMY
Growth Portfolio drives double-digit revenue growth as legacy products decline. - DETEC
2025 ended with lower sales and profit, but double-digit growth is forecast for early 2026. - ROCK
2025 revenue up 2.7% ex-Russia; 2026 EBIT margin guided at 13%-14% with high CapEx. - MCFT
Q2 FY2026 sales and margins surged, with guidance raised and a key acquisition announced. - QIGD
Revenue up 2%, net profit down 4%, and cash fell 22% amid higher export costs. - POWERINDIA
Q3 FY26 saw 29.6% revenue growth, 90.3% PAT jump, and a record order backlog. - AURIONPRO
26% revenue growth, strong margins, major wins, and AI-driven expansion mark the period. - XPO
Q4 2025 delivered margin expansion, record LTL service, and flat adjusted EPS year-over-year. - GPRE
Returned to profitability in Q4 2025 with strong margins, tax credits, and debt reduction. - MERUS
Net sales up 52.5% to €54.6m, EBITDA positive, with strong energy storage and power quality orders.
Next SoftOx Solutions earnings date
Q4 20255 Mar, 2026
SoftOx Solutions
Next SoftOx Solutions earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
SoftOx Solutions operates as a biotech company. The company focuses on the development of medical devices for diagnostics and treatment of tissue injury and other diseases. Its products include SoftOx Endo, which is used to treat tissue deterioration in the esophagus; and SoftOx Burn, which is used to prevent scarring following burn injuries.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage